Stabilized angiopoietin-2 antibodies and uses thereof
Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.
1. An isolated antibody that binds to angiopoietin-2 (Ang-2), wherein the antibody comprises a heavy chain variable region of SEQ ID No:7 (MEDI5) and a light chain variable region selected from the group consisting of:
a) SEQ ID No:3 (MEDI1);
b) SEQ ID No:4 (MEDI2);
c) SEQ ID No:5 (MEDI3);
d) SEQ ID No:6 (MEDI4); and
e) SEQ ID No:8 (MEDI6).
2. The antibody according to claim 1 , wherein the antibody comprises the light chain variable region of SEQ ID No:3 (MEDI1).
3. The antibody according to claim 1 , wherein the antibody, when produced, exhibits a production efficiency in a mammalian host cell equal to or greater than 2 times the production efficiency of an Ang-2 antibody comprising SEQ ID No: 1 and SEQ ID No: 2 (3.19.3).
4. The antibody according to claim 1 , wherein exhibits an aggregation rate that is at least 10% lower than the aggregation rate of an Ang-2 antibody comprising SEQ ID No: 1 and SEQ ID No: 2 (3.19.3).
5. The antibody according to claim 1 , wherein exhibits a melting temperature that is higher than the melting temperature of an Ang-2 antibody comprising SEQ ID No: 1 and SEQ ID No: 2 (3.19.3).
6. The antibody according to claim 1 , wherein the antibody comprises the light chain variable region of SEQ ID No:4 (MEDI2).
7. The antibody according to claim 1 , wherein the antibody comprises the light chain variable region of SEQ ID No:5 (MEDI3).
8. The antibody according to claim 1 , wherein the antibody comprises the light chain variable region of SEQ ID No:6 (MEDI4).
9. The antibody according to claim 1 , wherein the antibody comprises the light chain variable region of SEQ ID No:8 (MEDI6).
10. A pharmaceutical composition comprising:
a) an excipient; and
b) an isolated antibody that binds to Ang-2, wherein the antibody comprises a heavy chain variable region of SEQ ID No:7 (MEDI5) and a light chain variable region selected from the group consisting of:
i) SEQ ID No:3 (MEDI1);
ii) SEQ ID No:4 (MEDI2);
iii) SEQ ID No:5 (MEDI3);
iv) SEQ ID No:6 (MEDI4); and
v) SEQ ID No:8 (MEDI6).
11. The pharmaceutical composition according to claim 10 , wherein the antibody comprises the light chain variable region of SEQ ID No:3 (MEDI1).
12. The pharmaceutical composition according to claim 10 , wherein the antibody comprises the light chain variable region of SEQ ID No:4 (MEDI2).
13. The pharmaceutical composition according to claim 10 , wherein the antibody comprises the light chain variable region of SEQ ID No:5 (MEDI3).
14. The pharmaceutical composition according to claim 10 , wherein the antibody comprises the light chain variable region of SEQ ID No:6 (MEDI4).
15. The pharmaceutical composition according to claim 10 , wherein the antibody comprises the light chain variable region of SEQ ID No:8 (MEDI6).